scholarly journals A case of vitiligo regression in a patient with psoriasis and psoriatic arthritis receiving adalimumab therapy

2021 ◽  
Vol 15 (6) ◽  
pp. 106-110
Author(s):  
N. S. Rudneva ◽  
E. V. Natarova ◽  
V. N. Sorotskaya ◽  
T. G. Sadunashvili
Keyword(s):  
Psoriatic Arthritis ◽  
Drug Therapy ◽  
Autoimmune Thyroiditis ◽  
Skin Diseases ◽  
Skin Pigmentation ◽  
Adalimumab Therapy ◽  
The Common ◽  
Disease Modifying ◽  
Antirheumatic Drug Therapy ◽  
Disease Modifying Antirheumatic Drug

The article discusses the common pathogenetic pathways of autoimmune skin diseases – psoriasis and vitiligo. Currently proposed treatments for vitiligo do not significantly reduce or completely restore skin pigmentation. The use of adalimumab for 6 years in a patient suffering from psoriasis, psoriatic arthritis (PsA), vitiligo and autoimmune thyroiditis made it possible to control the activity of psoriasis and PsA, and also contributed to the regression of depigmentation foci. The use of biologic disease-modifying antirheumatic drug therapy in this group of patients in order to achieve repigmentation may be promising. 

scholarly journals Hepatitis B Screening Before Biologic or Targeted Synthetic Disease-modifying Antirheumatic Drug Therapy: Many Roads to Improvement

2021 ◽  
pp. jrheum.211000
Author(s):  
Alfredo Aguirre ◽  
Jinoos Yazdany
Keyword(s):  
Drug Therapy ◽  
Hepatitis B ◽  
Hbv Reactivation ◽  
Disease Modifying Antirheumatic Drugs ◽  
Antirheumatic Drugs ◽  
B Virus ◽  
Disease Modifying ◽  
Hepatitis B Screening ◽  
Antirheumatic Drug Therapy ◽  
Disease Modifying Antirheumatic Drug

Biologic and targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) have long been recognized to cause hepatitis B virus (HBV) reactivation in individuals chronically infected with or previously exposed to HBV.1 Despite this knowledge, many patients treated with b/tsDMARDs experience HBV reactivation each year because of inconsistent screening.2

Sign in / Sign up

Export Citation Format

Share Document